Annals of Surgical Oncology

, Volume 14, Issue 8, pp 2270–2280 | Cite as

Learning Curve for Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy—A Journey to Becoming a Nationally Funded Peritonectomy Center

  • Tristan D. Yan
  • Matthew Links
  • Sal Fransi
  • Theresa Jacques
  • Deborah Black
  • Vanessa Saunders
  • David L. Morris
Gastrointestinal Oncology

Abstract

Background

Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) for peritoneal surface malignancy is associated with a morbidity rate of 30–50% and a mortality rate of 1–10%. Recently, the St George Hospital in Sydney has been commissioned as the Nationally Funded Center for treatment of peritoneal surface malignancy in Australia.

Methods

The clinical and treatment-related data regarding 140 consecutive patients were prospectively collected. A comparison between the initial 70 patients (Group I) and the subsequent 70 patients (Group II) was performed. Univariate and multivariate analyses were conducted to identify the significant risk factors for moderate to severe morbidity.

Results

The hospital mortality was 4%. Sixty-one patients (44%) had moderate morbidity. Twenty-eight patients (20%) experienced severe morbidity. The mean hospital stay was 30 days. Twenty-seven patients (19%) were readmitted after initial discharge for management of delayed complications. The severe morbidity rate reduced from 30% to 10%, and the delayed morbidity rate reduced from 29% to 10%, when comparing Groups I and II. There were also reduced transfusion requirement, duration of operation, and intensive care unit stay. In the multivariate analysis, Group I (vs Group II; P = .005), performing small bowel resection (P = .005), and >4 peritonectomy procedures (vs ≤ 4; P = .013) were the three independent risk factors for severe complications.

Conclusions

The study suggests that there is a learning curve associated with this procedure. With accumulated experience in this procedure, an acceptable morbidity rate can be achieved.

Keywords

Cytoreductive surgery Intraperitoneal chemotherapy Colorectal peritoneal carcinomatosis Pseudomyxoma peritonei Peritoneal surface malignancy Peritoneal mesothelioma Learning curve Morbidity and mortality 

Notes

ACKNOWLEDGMENTS

The authors indicate that there are no potential conflicts of interests. Authors thank Jing Zhao, MD, for maintaining the peritonectomy database.

References

  1. 1.
    Gonzalez-Moreno S. Peritoneal Surface Oncology: A progress report. Eur J Surg Oncol 2006;32:593–6PubMedCrossRefGoogle Scholar
  2. 2.
    Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy of cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol 2007;14:484–9PubMedCrossRefGoogle Scholar
  3. 3.
    Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011–9PubMedCrossRefGoogle Scholar
  4. 4.
    Yan TD, Welch L, Black D, Sugarbaker P. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2006;DOI:10.1093/annonc/mdl428Google Scholar
  5. 5.
    Moran BJ. Establishment of a peritoneal malignancy treatment centre in the United Kingdom. Eur J Surg Oncol 2006;32:614–8PubMedCrossRefGoogle Scholar
  6. 6.
    Deraco M, Nonaka D, Baratti D, et al. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2006;13:229–37PubMedCrossRefGoogle Scholar
  7. 7.
    Smeenk RM, Verwaal VJ, Antonini N, Zoetmulder FA. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome. Ann Surg Oncol 2007;14:493–9PubMedCrossRefGoogle Scholar
  8. 8.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–43PubMedCrossRefGoogle Scholar
  9. 9.
    Loungnarath R, Causeret S, Bossard N, et al. Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study. Dis Colon Rectum 2005;48:1372–9PubMedCrossRefGoogle Scholar
  10. 10.
    Bradley RF, Stewart JH, Russell GB, et al. Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol 2006;30:551–9PubMedCrossRefGoogle Scholar
  11. 11.
    Yan TD, Links M, Xu ZY, et al. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal mucinous neoplasms. Br J Surg 2006;93:1270–6PubMedCrossRefGoogle Scholar
  12. 12.
    Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 2006;7:69–76PubMedCrossRefGoogle Scholar
  13. 13.
    Younan R, Kusamura S, Baratti D, et al. Bowel complications in 203 cases of peritoneal surface malignancies treated with peritonectomy and closed-technique intraperitoneal hyperthermic perfusion. Ann Surg Oncol 2005;12:910–8PubMedCrossRefGoogle Scholar
  14. 14.
    Yan TD, Alderman R, Edwards G, Sugarbaker P. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol 2007;14:515–5PubMedCrossRefGoogle Scholar
  15. 15.
    Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006;13:635–44PubMedCrossRefGoogle Scholar
  16. 16.
    Smeenk RM, Verwaal VJ, Zoetmulder FA. Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei—a report of 103 procedures. Eur J Surg Oncol 2006;32:186–90PubMedCrossRefGoogle Scholar
  17. 17.
    Moran BJ, Mukherjee A, Sexton R. Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100–4PubMedCrossRefGoogle Scholar
  18. 18.
    Glehen O, Osinsky D, Cotte E, et al. Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures. Ann Surg Oncol 2003;10:863–9PubMedCrossRefGoogle Scholar
  19. 19.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treatment Res 1996;82:359–74Google Scholar
  20. 20.
    Sugarbaker PH. Peritonectomy procedures Ann Surg 1995;221:29–42PubMedCrossRefGoogle Scholar
  21. 21.
    Esquivel J, Vidal-Jove J, Steves MA, Sugarbaker PH. Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy. Surgery 1993;113:631–6PubMedGoogle Scholar
  22. 22.
    Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995;221:124–32PubMedCrossRefGoogle Scholar
  23. 23.
    Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 1996;77:2622–9PubMedCrossRefGoogle Scholar
  24. 24.
    Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6:790–6PubMedCrossRefGoogle Scholar
  25. 25.
    Yan TD, Alderman R, Edwards G, Sugarbaker P. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 15:515–25CrossRefGoogle Scholar
  26. 26.
    Department of Health (UK) 2002, National Specialist Commission Advisory Group Annual Report 2001–2002, DH Publications, LondonGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Tristan D. Yan
    • 1
  • Matthew Links
    • 2
  • Sal Fransi
    • 3
  • Theresa Jacques
    • 4
  • Deborah Black
    • 5
  • Vanessa Saunders
    • 1
  • David L. Morris
    • 1
  1. 1.Nationally Funded Peritonectomy Center, Department of SurgeryUniversity of New South WalesSydneyAustralia
  2. 2.Department of Medical OncologySt George HospitalSydneyAustralia
  3. 3.Department of AnesthesiologySt George HospitalSydneyAustralia
  4. 4.Intensive Care UnitSt George HospitalSydneyAustralia
  5. 5.School of Public Health and Community MedicineUniversity of New South WalesSydneyAustralia

Personalised recommendations